πŸ‡ΊπŸ‡Έ FDA
Patent

US 11883431

T-cells modified to overexpress PHF19

granted A61KA61K40/11A61K40/4273

Quick answer

US patent 11883431 (T-cells modified to overexpress PHF19) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K40/11, A61K40/4273, A61P, A61P31/12